First Release

Selected Science papers are published online ahead of print. Some editorial changes may occur between the First Release version and the final printed version.

13 Apr 2023

A magnified compact galaxy at redshift 9.51 with strong nebular emission lines

BY
- Hayley Williams
- Patrick L. Kelly
- Wenlei Chen
- Gabriel Brammer
- Adi Zitrin
- Tommaso Treu
- Claudia Scarlata
- Anton M. Koekemoer
- Masamune Oguri
- Yu-Heng Lin
- Jose M. Diego
- Mario Nonino
- Jens Hjorth
- Danial Langeroodi
- Tom Broadhurst
- Noah Rogers
- Ismael Perez-Fournon
- Ryan J. Foley
- Saurabh Jha
- Alexei V. Filippenko
- Lou Strolger
- Justin Pierel
- Frederick Poidevin
- Lilan Yang
13 Apr 2023
Free

Abstract

Ultraviolet light from early galaxies is thought to have ionized gas in the intergalactic medium. However, there are few observational constraints on this epoch, due to the faintness of those galaxies and the redshift of their optical light into the ...

Judicial interference with mifepristone

BY
- Margaret Hamburg
- Joshua Sharfstein
13 Apr 2023
FULL ACCESS

06 Apr 2023

Structure of the R2 non-LTR retrotransposon initiating target-primed reverse transcription

BY
- Max E. Wilkinson
- Chris J. Frangieh
- Rhiannon K. Macrae
- Feng Zhang
06 Apr 2023
NO ACCESS

Abstract

Non-LTR retrotransposons, or Long Interspersed Nuclear Elements (LINEs), are an abundant class of eukaryotic transposons that insert into genomes by target-primed reverse transcription (TPRT). During TPRT, a target DNA sequence is nicked and primes ...

30 Mar 2023

Base editing rescue of spinal muscular atrophy in cells and in mice

BY
- Mandana Arbab
- Zaneta Matuszek
- Kaitlyn M. Kray
- Ailing Du
- Gregory A. Newby
- Anton J. Blatnik
- Aditya Raguram
- Michelle F. Richter
- Kevin T. Zhao
- Jonathan M. Levy
- Max W. Shen
- W. David Arnold
- Dan Wang
- Jun Xie
- Guangping Gao
- Arthur H. M. Burghes
- David R. Liu
30 Mar 2023
NO ACCESS

Abstract

Spinal muscular atrophy (SMA), the leading genetic cause of infant mortality, arises from SMN protein insufficiency following SMN1 loss. Approved therapies circumvent endogenous SMN regulation and require repeated dosing or may wane. We describe genome ...